Expanding while keeping an eye on the movements of the USA market.
The Nikkei average rebounded for the first time in three days, closing at 38,283.85 yen, up 257.68 yen (volume estimated at approximately 1.608 billion shares). Following NVIDIA's rebound in the previous day's US market, stocks in the semiconductor sector rose in the Tokyo market. In addition, buying aimed at autonomous rebound from the previous day's decline increased, pushing the Nikkei average up to 38,420.63 yen before the morning close. However, there is caution towards weekend position adjustments and assessing the situation in Russia and Ukraine.
The Nikkei Average rebounded, semiconductors-related stocks rose, but trading remains sluggish.
On the 21st, the U.S. stock market rose. The dow inc average finished up 461.88 points at 43,870.35, and the nasdaq closed up 6.28 points at 18,972.42. Concerns about geopolitical risks eased, and the market rose after the opening. When Chicago Fed President Goolsbee indicated that interest rates would be "below the current level" next year, buying activity based on expectations of falling interest rates pushed the market higher. Although the nasdaq struggled with the rise in long-term interest rates, it received positive sentiment from the earnings report of the semiconductor company nvidia.
Asahi Kogyo Co., Ltd. hits a new high [stocks hitting new highs and lows].
Top gainers on the Tokyo Stock Exchange's main board include Obayashi Corporation <1802> and Asahi Kogyo Co., Ltd. <1975> among 27 others. Top losers on the Tokyo Stock Exchange's main board include Asclepius Co., Ltd. <2678> and Create SD Holdings Co., Ltd. <3148> among 12 others. "Tokyo Stock Exchange Prime" "Tokyo Stock Exchange Standard" "Tokyo Stock Exchange Growth" new highs new lows new highs new lows new highs new lows 11/22 2712 1810 1491 11/21 3422 2313 1388 11/20 2928 2314 1061 11/19.
KaioM etc. continue to rank in, continuing clues regarding the license agreement with Asahi Kasei Pharma.
Kaiomu <4583> has ranked in (as of 14:32). Significant continued rise. After the market closed on the 20th, the company announced the conclusion of an exclusive licensing agreement with Asahi Kasei Pharma for its therapeutic antibody "Humanized Anti-CX3CR1 Antibody (PFKR)" and hit the stop-high yesterday. The buying star continues today. In addition to receiving 0.2 billion yen as a contract signing fee, Kaiomu will receive up to about 24.8 billion yen in milestone payments depending on the progress of future development and sales. Furthermore, after the product launch, it's expected to.
Toyo Suisan, Chuo Pharmaceutical etc (additional) Rating
Upgrade - Bullish Code Stock Name Securities Company Previous After Change ------------------------------------------------------- <1802> Obayashi Corporation SMBC Nikko Securities "2" "1" <1808> Haseko Corporation SMBC Nikko Securities "2" "1" Downgrade - Bearish Code Stock Name Securities Company Previous After Change ------------------------------------------------------- <3382>
Rating [security companies rating]
Upgrade - Bullish Code Stock Name Securities Company Conventional Change After --------------------------------------------- <1802> Obayashi Corporation SMBC Nikko Securities "2" "1" <1808> Haseko Corporation SMBC Nikko Securities "2" "1" Downgrade - Bearish Code Stock Name Securities Company Conventional Change After --------------------------------------------- <9605> Toei Company